[{"orgOrder":0,"company":"Sanaria","sponsor":"Sanaria","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Atovaquone","moa":"Cytochrome b","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Sanaria","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanaria \/ Sanaria","highestDevelopmentStatusID":"6","companyTruncated":"Sanaria \/ Sanaria"},{"orgOrder":0,"company":"Sanaria","sponsor":"National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cytotoxic Drug","year":"2017","type":"Inapplicable","leadProduct":"Pyrimethamine","moa":"Dihydrofolate reductase","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Sanaria","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanaria \/ Sanaria","highestDevelopmentStatusID":"6","companyTruncated":"Sanaria \/ Sanaria"},{"orgOrder":0,"company":"Sanaria","sponsor":"University of Oxford","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Microorganism","year":"2011","type":"Inapplicable","leadProduct":"Plasmodium Falciparum Sporozoites","moa":"Immune","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Sanaria","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanaria \/ Sanaria","highestDevelopmentStatusID":"6","companyTruncated":"Sanaria \/ Sanaria"},{"orgOrder":0,"company":"Sanaria","sponsor":"Radboud University Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2010","type":"Inapplicable","leadProduct":"P. Falciparum Sporozoites","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Sanaria","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanaria \/ Radboud University Medical Center","highestDevelopmentStatusID":"6","companyTruncated":"Sanaria \/ Radboud University Medical Center"},{"orgOrder":0,"company":"Sanaria","sponsor":"Ifakara Health Institute | Swiss Tropical and Public Health Institute","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2012","type":"Inapplicable","leadProduct":"P. Falciparum Sporozoites","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Sanaria","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanaria \/ Ifakara Health Institute | Swiss Tropical and Public Health Institute","highestDevelopmentStatusID":"6","companyTruncated":"Sanaria \/ Ifakara Health Institute | Swiss Tropical and Public Health Institute"},{"orgOrder":0,"company":"Sanaria","sponsor":"Institute of Tropical Medicine, University of Tuebingen","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2012","type":"Inapplicable","leadProduct":"P. Falciparum Sporozoites","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Sanaria","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanaria \/ Institute of Tropical Medicine, University of Tuebingen","highestDevelopmentStatusID":"6","companyTruncated":"Sanaria \/ Institute of Tropical Medicine, University of Tuebingen"},{"orgOrder":0,"company":"Sanaria","sponsor":"Radboud University Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2012","type":"Inapplicable","leadProduct":"P. Falciparum Sporozoites","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Sanaria","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanaria \/ Radboud University Medical Center","highestDevelopmentStatusID":"6","companyTruncated":"Sanaria \/ Radboud University Medical Center"},{"orgOrder":0,"company":"Sanaria","sponsor":"Barcelona Centre for International Health Research","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2013","type":"Inapplicable","leadProduct":"P. Falciparum Sporozoites","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Sanaria","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanaria \/ Barcelona Centre for International Health Research","highestDevelopmentStatusID":"6","companyTruncated":"Sanaria \/ Barcelona Centre for International Health Research"},{"orgOrder":0,"company":"Sanaria","sponsor":"Institute of Tropical Medicine, University of Tuebingen | German Federal Ministry of Education and Research","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2014","type":"Inapplicable","leadProduct":"P. Falciparum Sporozoites","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Sanaria","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanaria \/ Institute of Tropical Medicine, University of Tuebingen | German Federal Ministry of Education and Research","highestDevelopmentStatusID":"6","companyTruncated":"Sanaria \/ Institute of Tropical Medicine, University of Tuebingen | German Federal Ministry of Education and Research"},{"orgOrder":0,"company":"Sanaria","sponsor":"Centre de Recherche M\u00e9dicale de Lambar\u00e9n\u00e9 | Institute of Tropical Medicine, University of Tuebingen","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2014","type":"Inapplicable","leadProduct":"P. Falciparum Sporozoites","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Sanaria","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanaria \/ Centre de Recherche M\u00e9dicale de Lambar\u00e9n\u00e9 | Institute of Tropical Medicine, University of Tuebingen","highestDevelopmentStatusID":"6","companyTruncated":"Sanaria \/ Centre de Recherche M\u00e9dicale de Lambar\u00e9n\u00e9 | Institute of Tropical Medicine, University of Tuebingen"},{"orgOrder":0,"company":"Sanaria","sponsor":"Malaria Research and Training Center, Bamako, Mali | University of the Sciences, Techniques and Technologies of Bamako | National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Pf Sporozoites Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Sanaria","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanaria \/ Malaria Research and Training Center, Bamako, Mali | University of the Sciences, Techniques and Technologies of Bamako | National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"8","companyTruncated":"Sanaria \/ Malaria Research and Training Center, Bamako, Mali | University of the Sciences, Techniques and Technologies of Bamako | National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"Sanaria","sponsor":"Naval Medical Research Center | University of Maryland | Walter Reed Army Institute of Research | Joint Warfighter Medical Research Program","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2015","type":"Inapplicable","leadProduct":"Pfspz Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Sanaria","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Sanaria \/ Naval Medical Research Center | University of Maryland | Walter Reed Army Institute of Research | Joint Warfighter Medical Research Program","highestDevelopmentStatusID":"8","companyTruncated":"Sanaria \/ Naval Medical Research Center | University of Maryland | Walter Reed Army Institute of Research | Joint Warfighter Medical Research Program"},{"orgOrder":0,"company":"Sanaria","sponsor":"Eijkman Oxford Clinical Research Unit | Indonesia University | Congressionally Directed Medical Research Programs","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2018","type":"Inapplicable","leadProduct":"Pfspz Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Sanaria","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Sanaria \/ Eijkman Oxford Clinical Research Unit | Indonesia University | Congressionally Directed Medical Research Programs","highestDevelopmentStatusID":"8","companyTruncated":"Sanaria \/ Eijkman Oxford Clinical Research Unit | Indonesia University | Congressionally Directed Medical Research Programs"},{"orgOrder":0,"company":"Sanaria","sponsor":"Centre de Recherches M\u00e9dicales de Lambar\u00e9n\u00e9, German Center for Infection Research","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2018","type":"Inapplicable","leadProduct":"Pfspz Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Sanaria","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Sanaria \/ Centre de Recherches M\u00e9dicales de Lambar\u00e9n\u00e9, German Center for Infection Research","highestDevelopmentStatusID":"8","companyTruncated":"Sanaria \/ Centre de Recherches M\u00e9dicales de Lambar\u00e9n\u00e9, German Center for Infection Research"},{"orgOrder":0,"company":"Sanaria","sponsor":"Kenya Medical Research Institute | Centers for Disease Control and Prevention | National Institutes of Health | University of Maryland","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2016","type":"Inapplicable","leadProduct":"Pfspz Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Sanaria","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Sanaria \/ Kenya Medical Research Institute | Centers for Disease Control and Prevention | National Institutes of Health | University of Maryland","highestDevelopmentStatusID":"8","companyTruncated":"Sanaria \/ Kenya Medical Research Institute | Centers for Disease Control and Prevention | National Institutes of Health | University of Maryland"},{"orgOrder":0,"company":"Sanaria","sponsor":"Ifakara Health Institute | Swiss Tropical and Public Health Institute | Tanzania Commission for Science and Technology","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2014","type":"Inapplicable","leadProduct":"Pfspz Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Sanaria","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Sanaria \/ Ifakara Health Institute | Swiss Tropical and Public Health Institute | Tanzania Commission for Science and Technology","highestDevelopmentStatusID":"8","companyTruncated":"Sanaria \/ Ifakara Health Institute | Swiss Tropical and Public Health Institute | Tanzania Commission for Science and Technology"},{"orgOrder":0,"company":"Sanaria","sponsor":"Naval Medical Research Center | Walter Reed Army Institute of Research | Military Infectious Diseases Research Program","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2014","type":"Inapplicable","leadProduct":"Pfspz Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Sanaria","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Sanaria \/ Naval Medical Research Center | Walter Reed Army Institute of Research | Military Infectious Diseases Research Program","highestDevelopmentStatusID":"8","companyTruncated":"Sanaria \/ Naval Medical Research Center | Walter Reed Army Institute of Research | Military Infectious Diseases Research Program"},{"orgOrder":0,"company":"Sanaria","sponsor":"Ifakara Health Institute | Swiss Tropical and Public Health Institute | Government of Equatorial Guinea | Hospital Universitario La Paz | Marathon Oil Corporation | Noble Oil Services","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2015","type":"Inapplicable","leadProduct":"Pfspz Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Sanaria","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Sanaria \/ Ifakara Health Institute | Swiss Tropical and Public Health Institute | Government of Equatorial Guinea | Hospital Universitario La Paz | Marathon Oil Corporation | Noble Oil Services","highestDevelopmentStatusID":"8","companyTruncated":"Sanaria \/ Ifakara Health Institute | Swiss Tropical and Public Health Institute | Government of Equatorial Guinea | Hospital Universitario La Paz | Marathon Oil Corporation | Noble Oil Services"},{"orgOrder":0,"company":"Sanaria","sponsor":"Ifakara Health Institute | Swiss Tropical and Public Health Institute | Medical Care Development | Tanzania Commission for Science and Technology | Government of Equatorial Guinea | Marathon Oil Corporation | Noble Oil Services","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2015","type":"Inapplicable","leadProduct":"Pfspz Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Sanaria","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Sanaria \/ Ifakara Health Institute | Swiss Tropical and Public Health Institute | Medical Care Development | Tanzania Commission for Science and Technology | Government of Equatorial Guinea | Marathon Oil Corporation | Noble Oil Services","highestDevelopmentStatusID":"8","companyTruncated":"Sanaria \/ Ifakara Health Institute | Swiss Tropical and Public Health Institute | Medical Care Development | Tanzania Commission for Science and Technology | Government of Equatorial Guinea | Marathon Oil Corporation | Noble Oil Services"},{"orgOrder":0,"company":"Sanaria","sponsor":"Institute of Tropical Medicine, University of Tuebingen | German Federal Ministry of Education and Research | German Center for Infection Research","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2016","type":"Inapplicable","leadProduct":"Pfspz Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Sanaria","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Sanaria \/ Institute of Tropical Medicine, University of Tuebingen | German Federal Ministry of Education and Research | German Center for Infection Research","highestDevelopmentStatusID":"8","companyTruncated":"Sanaria \/ Institute of Tropical Medicine, University of Tuebingen | German Federal Ministry of Education and Research | German Center for Infection Research"},{"orgOrder":0,"company":"Sanaria","sponsor":"Ifakara Health Institute | Swiss Tropical and Public Health Institute | Government of Equatorial Guinea | Marathon Oil Corporation | Noble Oil Services | La Paz Medical Center, Malabo, Equatorial Guinea","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2016","type":"Inapplicable","leadProduct":"Pfspz Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Sanaria","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Sanaria \/ Ifakara Health Institute | Swiss Tropical and Public Health Institute | Government of Equatorial Guinea | Marathon Oil Corporation | Noble Oil Services | La Paz Medical Center, Malabo, Equatorial Guinea","highestDevelopmentStatusID":"8","companyTruncated":"Sanaria \/ Ifakara Health Institute | Swiss Tropical and Public Health Institute | Government of Equatorial Guinea | Marathon Oil Corporation | Noble Oil Services | La Paz Medical Center, Malabo, Equatorial Guinea"},{"orgOrder":0,"company":"Sanaria","sponsor":"Ifakara Health Institute | Swiss Tropical and Public Health Institute | Medical Care Development","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2018","type":"Inapplicable","leadProduct":"Pfspz Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Sanaria","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Sanaria \/ Ifakara Health Institute | Swiss Tropical and Public Health Institute | Medical Care Development","highestDevelopmentStatusID":"8","companyTruncated":"Sanaria \/ Ifakara Health Institute | Swiss Tropical and Public Health Institute | Medical Care Development"},{"orgOrder":0,"company":"Sanaria","sponsor":"Ifakara Health Institute | Swiss Tropical and Public Health Institute | Government of Equatorial Guinea | Noble Oil Services | Marathon Oil Corporation | Atlantic Methanol Production Company | EG LNG","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2018","type":"Inapplicable","leadProduct":"Pfspz Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Sanaria","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Sanaria \/ Ifakara Health Institute | Swiss Tropical and Public Health Institute | Government of Equatorial Guinea | Noble Oil Services | Marathon Oil Corporation | Atlantic Methanol Production Company | EG LNG","highestDevelopmentStatusID":"8","companyTruncated":"Sanaria \/ Ifakara Health Institute | Swiss Tropical and Public Health Institute | Government of Equatorial Guinea | Noble Oil Services | Marathon Oil Corporation | Atlantic Methanol Production Company | EG LNG"},{"orgOrder":0,"company":"Sanaria","sponsor":"Fred Hutchinson Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Pfspz Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Sanaria","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Sanaria \/ Fred Hutchinson Cancer Center","highestDevelopmentStatusID":"8","companyTruncated":"Sanaria \/ Fred Hutchinson Cancer Center"},{"orgOrder":0,"company":"Sanaria","sponsor":"University of Maryland, Baltimore | National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Pfspz Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Sanaria","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Sanaria \/ University of Maryland, Baltimore | National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"8","companyTruncated":"Sanaria \/ University of Maryland, Baltimore | National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"Sanaria","sponsor":"EU Malaria Fund","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"PfSPZ Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Sanaria","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.02,"dosageForm":"Suspension","sponsorNew":"Sanaria \/ EU Malaria Fund","highestDevelopmentStatusID":"8","companyTruncated":"Sanaria \/ EU Malaria Fund"},{"orgOrder":0,"company":"Sanaria","sponsor":"Radboud University Medical Center | Leiden University Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2017","type":"Inapplicable","leadProduct":"PfSPZ-GA1 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Sanaria","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanaria \/ Radboud University Medical Center | Leiden University Medical Center","highestDevelopmentStatusID":"6","companyTruncated":"Sanaria \/ Radboud University Medical Center | Leiden University Medical Center"},{"orgOrder":0,"company":"Sanaria","sponsor":"University of Maryland, Baltimore | Groupe de Recherche Action en Sante | Seattle Children\u2019s Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"PfSPZ-LARC2 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Sanaria","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanaria \/ University of Maryland, Baltimore | Groupe de Recherche Action en Sante | Seattle Children\u2019s Hospital","highestDevelopmentStatusID":"6","companyTruncated":"Sanaria \/ University of Maryland, Baltimore | Groupe de Recherche Action en Sante | Seattle Children\u2019s Hospital"},{"orgOrder":0,"company":"Sanaria","sponsor":"Universit\u00e4tsklinikum T\u00fcbingen (Tropical Medicine Institute) | UCLA David Geffen School of Medicine | Stanford University | Leiden University","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"PfSPZ-LARC2 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Sanaria","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanaria \/ Universit\u00e4tsklinikum T\u00fcbingen (Tropical Medicine Institute) | UCLA David Geffen School of Medicine | Stanford University | Leiden University","highestDevelopmentStatusID":"6","companyTruncated":"Sanaria \/ Universit\u00e4tsklinikum T\u00fcbingen (Tropical Medicine Institute) | UCLA David Geffen School of Medicine | Stanford University | Leiden University"}]
Find Clinical Drug Pipeline Developments & Deals by Sanaria
Details :
PfSPZ-LARC2 Vaccine is a Vaccine drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Malaria, Falciparum.
Details :
PfSPZ-LARC2 Vaccine is a Vaccine drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Malaria, Falciparum.
Sponsor :
Malaria Research and Training Center, Bamako, Mali | University of the Sciences, Techniques and Technologies of Bamako | National Institute of Allergy and Infectious Diseases
Details :
Pf Sporozoites Vaccine is a Vaccine drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Malaria.
Sponsor :
Malaria Research and Training Center, Bamako, Mali | University of the Sciences, Techniques and Technologies of Bamako | National Institute of Allergy and Infectious Diseases
Details :
Sanaria’s PfSPZ Vaccine is a radiation-attenuated whole-organism vaccine, meaning it is a weakened form of the parasite that causes malaria. PfSPZ Vaccine elicits an immunological response in the body against the malaria pathogen, without the individua...
Sponsor :
Ifakara Health Institute | Swiss Tropical and Public Health Institute | Government of Equatorial Guinea | Noble Oil Services | Marathon Oil Corporation | Atlantic Methanol Production Company | EG LNG
Sponsor :
Ifakara Health Institute | Swiss Tropical and Public Health Institute | Government of Equatorial Guinea | Noble Oil Services | Marathon Oil Corporation | Atlantic Methanol Production Company | EG LNG
Reset All
